Literature DB >> 19277221

A syndrome resembling acute posterior multifocal placoid pigment epitheliopathy in older adults.

Alexander Taich1, Mark W Johnson.   

Abstract

PURPOSE: To describe clinical characteristics and visual and anatomic outcomes of a syndrome clinically similar to acute posterior multifocal placoid pigment epitheliopathy (APMPPE) in older patients.
METHODS: We retrospectively reviewed medical records and photographic studies of consecutive patients over the age of 50 who presented to an academic tertiary care center with acute-onset visual symptoms associated with flat, gray-white lesions at the level of the retinal pigment epithelium reminiscent of APMPPE. Main outcome measures were visual acuity and macular anatomic status at the final follow-up visit.
RESULTS: The cohort included 4 men and 2 women with a median age of 72.5 (range, 58-82) years. The disease course was characterized by recurrent episodes in 6 of 11 eyes (55%), with initial or eventual bilaterality in all 5 binocular patients. Five of 6 patients were treated with corticosteroids, and all 6 patients experienced significant short-term improvement in visual acuity. However, 8 of 11 eyes (73%) developed progressive geographic atrophy, and 7 (64%) developed choroidal neovascularization. With a mean (+/- SD) follow-up time of 6.6 +/- 5.5 years, the final visual acuity was 20/200 or worse in 8 of 11 eyes (73%).
CONCLUSIONS: Although older patients presenting with APMPPE-like lesions are likely to experience visual improvement as acute lesions resolve, progression to geographic atrophy and choroidal neovascular membrane formation is the usual long-term outcome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19277221      PMCID: PMC2646434     

Source DB:  PubMed          Journal:  Trans Am Ophthalmol Soc        ISSN: 0065-9533


  13 in total

1.  Persistent placoid maculopathy: a new clinical entity.

Authors:  Pamela R Golchet; Lee M Jampol; David Wilson; Lawrence A Yannuzzi; Michael Ober; Edward Stroh
Journal:  Ophthalmology       Date:  2007-08       Impact factor: 12.079

Review 2.  Serpiginous choroiditis.

Authors:  Wee-Kiak Lim; Ronald R Buggage; Robert B Nussenblatt
Journal:  Surv Ophthalmol       Date:  2005 May-Jun       Impact factor: 6.048

3.  Acute posterior multifocal placoid pigment epitheliopathy: a long-term study.

Authors:  T V Roberts; P Mitchell
Journal:  Aust N Z J Ophthalmol       Date:  1997-11

4.  Acute posterior multifocal placoid pigment epitheliopathy.

Authors:  J D Gass
Journal:  Arch Ophthalmol       Date:  1968-08

5.  Relentless placoid chorioretinitis: A new entity or an unusual variant of serpiginous chorioretinitis?

Authors:  B E Jones; L M Jampol; L A Yannuzzi; M Tittl; M W Johnson; D P Han; J L Davis; D F Williams
Journal:  Arch Ophthalmol       Date:  2000-07

6.  Acute multifocal posterior placoid pigment epitheliopathy: a theory of pathogenesis.

Authors:  D Park; H Schatz; H R McDonald; R N Johnson
Journal:  Retina       Date:  1995       Impact factor: 4.256

7.  Acute posterior multifocal placoid pigment epitheliopathy. A follow up study.

Authors:  B E Damato; M Nanjiani; W S Foulds
Journal:  Trans Ophthalmol Soc U K       Date:  1983

8.  Acute syphilitic posterior placoid chorioretinitis.

Authors:  J D Gass; R A Braunstein; R G Chenoweth
Journal:  Ophthalmology       Date:  1990-10       Impact factor: 12.079

9.  Macular geographic helicoid choroidopathy.

Authors:  R A Hardy; H Schatz
Journal:  Arch Ophthalmol       Date:  1987-09

10.  Macular serpiginous choroiditis.

Authors:  A M Mansour; L M Jampol; K H Packo; N F Hrisomalos
Journal:  Retina       Date:  1988       Impact factor: 4.256

View more
  2 in total

1.  ACUTE POSTERIOR MULTIFOCAL PLACOID PIGMENT EPITHELIOPATHY FOLLOWING INFLUENZA VACCINATION.

Authors: 
Journal:  Rom J Ophthalmol       Date:  2015 Jan-Mar

2.  Untreated Acute Posterior Multifocal Placoid Pigment Epitheliopathy (APMPPE): a case series.

Authors:  Olivia Xerri; Sawsen Salah; Dominique Monnet; Antoine P Brézin
Journal:  BMC Ophthalmol       Date:  2018-03-20       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.